magine a world where we are able to prevent and pre-empt the burden of cardiovascular, lung, and blood diseases, a world where we are able to cap- 
BUILDING ON THE LEGACY OF SUCCESS
The mission of the National Heart, Lung, and Blood Institute (NHLBI) is to enhance public health by transforming research discoveries in heart, lung, blood, and sleep (HLBS) systems into improved disease prevention and treatment. The NHLBI is building on a history of research excellence by embarking on a Strategic Visioning process to collectively identify the greatest unmet needs in HLBS research. Our aim is to engage all corners of the NHLBI community to identify the most compelling scientific questions of our time, questions that address pressing public health challenges, capitalize on major advances in technology, and take bold new approaches that, because of their scope and complexity, transcend any individual laboratory or organization, and require NHLBI leadership (Figure 1 ). Investigator-initiated research (e.g., R01 awards) makes up the majority (z80%) of the NHLBI extramural budget. We have every intention to maintain our high level of commitment to investigator-initiated fundamental discovery science; it is our top priority. This Strategic Visioning process will largely inform our investments that focus on NHLBI-initiated solicitations (e.g., requests for applications, z20% of extramural research funds) designed to catalyze the pursuit of investigations into important yet unexplored scientific areas. Although the Strategic Visioning process will guide institute-initiated activities, it may also provide additional insights for individual investigatorinitiated programs.
For >60 years, the NHLBI community has fostered a legacy of research excellence through groundbreaking fundamental discovery science, landmark clinical trials and population-based cohort studies, and innovative health education and dissemination efforts. For example, in the cardiovascular arena, the Framingham Heart Study led to the identification of cholesterol as a major risk factor for heart disease (1).
Subsequent NHLBI-supported fundamental discovery science identified pathways of cholesterol synthesis From the *National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; and the yNational that paved the road for the development of statins (2), a major contributor to the dramatic 75% reduction in coronary heart disease since 1968 (3, 4) . Today, exome sequencing technology is identifying rare genomic variants such as those in the apolipoprotein C3 gene (APOC3) that result in lower triglyceride levels and a lower risk of heart attack, which could lead to the development of next-generation drugs that can more effectively prevent heart disease (5).
Exciting new technologies are also changing how we capitalize on these discoveries to arrest, or possibly even reverse, disease pathobiology. For example, researchers have developed high-density lipoprotein nanoparticle carriers that can deliver statins directly to atherosclerotic plaques and inhibit plaque progression or induce plaque regression (6) . The National Heart, Lung, and Blood Institute (NHLBI) Advisory Council and the Board of External Experts met jointly in September 2014 to create the initial outline for the Strategic Visioning process. The NHLBI staff then developed a full Strategic Visioning Framework to elicit and collect scientific compelling questions (CQs) and critical challenges (CCs) from the NHLBI community. In spring 2015, the entire NHLBI community will contribute CQs and CCs. These CQs and CCs will be refined, integrated, and evaluated against the NHLBI research portfolio to develop Draft Strategic Visioning Scientific Priorities, which will be released for public comment in summer 2015. The NHBLI, working with its scientific advisory groups, will select a final prioritized list of CQs and CCs and publish them as part of a Strategic Visioning Scientific Priorities document by early 2016 that will describe the strategic priorities of the NHLBI. 
PROVIDE YOUR PERSPECTIVE AND EXPERTISE
A major innovative feature of the Strategic Visioning process is the active, iterative, and grassroots engagement of the NHLBI community to identify bold and compelling scientific questions that NHLBI needs to address to promote HLBS health of all individuals.
FIGURE 2 Strategic Goals Supporting the NHLBI Mission
The Strategic Goals Supporting the National Heart, Lung, and Blood Institute mission encompass understanding human health and disease, translating basic research into preventive and therapeutic interventions, and developing a biomedical workforce with the necessary skills and tools for heart, lung, blood, and sleep (HLBS) research. 
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